Vial cracking causes halt in lupus drug trial

Cracked vials have led to the suspension of a clinical trial. Biotech drug developer Anthera found the cracks in vials of its experimental lupus drug, A-623, which is in Phase IIb testing.

The company announced Tuesday that it has suspended dosing and enrollment in the trial while it investigates.

Faulty vials were discovered by a clinical investigator at one of the trial sites. Upon investigation, the company found additional cracked vials in the drug storeroom of another facility. CEO Paul Truex says in a release that he's committed to resolving the issue and discussing plans with the FDA.

- see the Anthera release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.